期刊文献+

Gain-of-function mutant p53 in cancer progression and therapy 被引量:34

原文传递
导出
摘要 p53 is a key tumor suppressor,and loss of p53 function is frequently a prerequisite for cancer development.The p53 gene is the most frequently mutated gene in human cancers;p53 mutations occur in>50%of all human cancers and in almost every type of human cancers.Most of p53 mutations in cancers are missense mutations,which produce the full-length mutant p53(mutp53)protein with only one amino acid difference from wild-type p53 protein.In addition to loss of the tumor-suppressive function of wild-type p53,many mutp53 proteins acquire new oncogenic activities independently of wild-type p53 to promote cancer progression,termed gain-of-function(GOF).Mutp53 protein often accumulates to very high levels in cancer cells,which is critical for its GOF.Given the high mutation frequency of the p53 gene and the GOF activities of mutp53 in cancer,therapies targeting mutp53 have attracted great interest.Further understanding the mechanisms underlying mutp53 protein accumulation and GOF will help develop effective therapies treating human cancers containing mutp53.In this review,we summarize the recent advances in the studies on mutp53 regulation and GOF as well as therapies targeting mutp53 in human cancers.
机构地区 [
出处 《Journal of Molecular Cell Biology》 SCIE CAS CSCD 2020年第9期674-687,共14页 分子细胞生物学报(英文版)
基金 This work was supported in part by grants from the National Institutes of Health(NIH R01CA227912 and R01CA214746)to Z.F.and grants from NIH(R01CA203965) Congressionally Directed Medical Research Programs(CDMRP W81XWH-16-1-0358 and W81XWH1810238)to W.H.
  • 相关文献

参考文献9

二级参考文献128

  • 1Cahilly-Snyder L, Yang-Feng T, Francke U and George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987, 13: 235-244.
  • 2Fakharzadeh SS, Trusko SP and George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991, 10: 1565-1569.
  • 3Roth J, Dobbelstein M, Freedman DA, Shenk T and Levine AJ. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17: 554-564.
  • 4Zhang Y and Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16: 369-377.
  • 5Lindstrom MS, Jin A, Deisenroth C, White Wolf G and Zhang Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol Cell Bioi 2007, 27: 1056-1068.
  • 6Boddy MN, Freemont PS and Borden KL. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem Sci 1994, 19: 198-199.
  • 7Honda R, Tanaka H and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressorp53. FEBS Lett 1997, 420: 25-27.
  • 8Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N and Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 2007, 26: 90-101.
  • 9Thrower JS, Hoffman L, Rechsteiner M and Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000, 19: 94-102.
  • 10Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997,88: 323-331.

共引文献97

同被引文献136

引证文献34

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部